menu
0
search
search
    close

    Bird Rock Bio

    Operator of a clinical-stage bio-pharmaceutical company focusing on the development of immuno-inflammatory regulators

      Description

      Operator of a clinical-stage bio-pharmaceutical company focusing on the development of immuno-inflammatory regulators. The company develops therapeutic antibodies with clinical and commercial differentiation against biologic targets with human proof of mechanism.

      Company Status

      The company raised $2.5 million of Series D venture funding from undisclosed investors on December 22, 2016, putting the pre-money valuation at $100 million. Previously, the company raised $9 million of Series C venture funding from 5AM Ventures, Versant Ventures and Apposite Capital in October 2016, putting the pre-money valuation at $71 million. SR One, Merck, Aravis and MS Ventures also participated.

      Primary Industry Sector / Group / Code
      Gallery
      Service Providers
      General Services
      NameType
      CooleyLegal Advisor
      EYAuditor
      Silicon Valley BankGeneral Business Banking
      Services on a Deal
      NameType
      CooleyLegal Advisor
      Silicon Valley BankDebt Financing
      Keywords
      disease treatment, immune based disease, non-alcoholic steatohepatitis, protein therapeutic, rheumatoid arthritis
      General Information
      • Company Former Name
        Anaphore, ImmunoNewCo, RuiYi
      • All Industries
        Biotechnology*, Drug Discovery, Other Pharmaceuticals and Biotechnology
      • Company Financing Status
        Venture Capital-Backed
      • Total Raised
        $68.70M
      • Business Status
        Clinical Trials - Phase 1
      • Ownership Status
        Privately Held (backing)
      • Universe
        Debt Financed, Venture Capital
      • Website
        http://www.birdrockbio.com
      • Year Founded
        2006
      Employees
      • Employees
        10
      • Employee History
      Investors
      Active Investors
      Website favicon5AM Ventures
      Website faviconApposite Capital
      Website faviconAravis
      Website faviconMerck
      Website faviconSR One
      Website faviconVersant Venture Management
      Former Investors
      Website faviconMerck Ventures
      Acquirers
      Signals Summary – Growth rates
      • Growth Rate
        0.16%
      • Growth Rate Percentile
        88
      • Growth Rate Change
        -0.05%
      • Growth Rate % Change
        -25.16%
      • Social Growth Rate
        0.16%
      • Social Growth Rate Percentile
        77
      • Twitter Growth Rate
        0.16%
      • Twitter Growth Rate Percentile
        81
      Signals Summary – Size multiple
      • Size Multiple
        0.68x
      • Size Multiple Percentile
        41
      • Size Multiple Change
        0.02x
      • Size Multiple % Change
        2.50%
      • Social Size Multiple
        0.68x
      • Social Size Multiple Percentile
        42
      • Twitter Size Multiple
        0.68x
      • Twitter Size Multiple Percentile
        43
      Social media signals
      • Facebook Likes
        15
      • Twitter Followers
        243
      First Financing
      • First Financing Date
        October 6, 2011
      • First Financing Size
        $38.20M
      • First Financing Size Status
        Actual
      • First Financing Valuation
        $50.20M
      • First Financing Valuation Status
        Actual
      • First Financing Deal Type
        Early Stage VC
      • First Financing Deal Type 2
        Series A
      • First Financing Deal Class
        Venture Capital
      • First Financing Status
        Completed
      Last Financing
      • Last Financing Date
        December 22, 2016
      • Last Financing Size
        $2.50M
      • Last Financing Size Status
        Actual
      • Last Financing Valuation
        $102.50M
      • Last Financing Valuation Status
        Actual
      • Last Financing Deal Type
        Later Stage VC
      • Last Financing Deal Type 2
        Series D
      • Last Financing Deal Class
        Venture Capital
      • Last Financing Status
        Completed
      Location
      Get Directions
      Primary Contact
      • Primary Contact
        Paul Grayson
      • Primary Contact Title
        Chief Executive Officer, President & Board Member
      • Primary Contact Email
        paul@birdrockbio.com
      • Primary Contact Phone
        +1 (858) 587-4815
      Headquarters
      • HQ Location
        2223 Avenida De La Playa, La Jolla, CA 92037, USA
      • HQ Address Line 1
        2223 Avenida de la Playa
      • HQ Address Line 2
        Suite 205
      • HQ City
        La Jolla
      • HQ State/Province
        California
      • HQ Post Code
        92037
      • HQ Country
        United States
      • HQ Phone
        +1 (858) 587-4815
      • HQ Fax
        +1 (858) 587-4854
      • HQ Email
        info@birdrockbio.com
      • HQ Global Region
        Americas
      • HQ Global Sub Region
        North America
      mood_bad
    • No comments yet.
      • chat
      Add a review

      Leave a Reply ·

      keyboard_arrow_up